Physician profile
Raza Hashmi
NPI 1447244306
$5,529.87
in general payments reported to CMS, 2019-2025
35 companies · $391 in 2025
The $391 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $953 · 2020: $915 · 2021: $1,154 · 2022: $968 · 2023: $663 · 2024: $485 · 2025: $391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,474 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,473.94 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $601.52 | 2019-2025 | Farxiga, Lokelma, Wainua |
| Janssen Pharmaceuticals, INC | $529.63 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $526.10 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $427.85 | 2019-2024 | Jardiance |
| Pfizer INC. | $427.75 | 2019-2025 | |
| Kestra Medical Technology Services, INC. | $400.96 | 2023-2024 | Assure Wcd |
| Amarin Pharma, INC. | $328.37 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $275.62 | 2019-2025 | Lifevest |
| Amgen INC. | $272.58 | 2019-2024 | Repatha |
| Esperion Therapeutics, INC. | $239.15 | 2020-2024 | Nexletol |
| Merck Sharp & Dohme LLC | $186.35 | 2022-2024 | Verquvo, Lynparza, Keytruda |
| Atricure, INC. | $172.54 | 2021-2022 | |
| Irhythm Technologies, INC. | $119.55 | 2022 | |
| Astellas Pharma US INC | $113.30 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $112.93 | 2019-2024 | Camzyos, Eliquis |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $104.80 | 2019 | |
| Penumbra, INC. | $95.78 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $94.47 | 2022-2023 | Uptravi, Opsumit |
| Novo Nordisk INC | $81.34 | 2023-2024 | Rybelsus, Ozempic |
| Boston Scientific Corporation | $71.57 | 2025 | Watchman Flx, Cds - Mct/Cem Monitoring |
| Kiniksa Pharmaceuticals International, Plc | $63.30 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $50.69 | 2019 | |
| Kiniksa Pharmaceuticals, Ltd. | $30.71 | 2023 | Arcalyst |
| Lundbeck LLC | $27.72 | 2019 | |
| Alnylam Pharmaceuticals INC. | $23.86 | 2025 | Onpattro |
| Bridgebio Pharma, INC. | $18.39 | 2025 | Attruby |
| Biodelivery Sciences International, INC. | $16.15 | 2020 | |
| Daiichi Sankyo INC. | $15.75 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $15.50 | 2019 | |
| Lilly USA, LLC | $15.07 | 2020 | |
| Bardy Diagnostics, INC. | $15.00 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.90 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $14.56 | 2023 | Inpefa |
| Glaxosmithkline, LLC. | $13.71 | 2020 | |
| Amryt Pharma Holdings Ltd | $12.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raza Hashmi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.